{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:18:41Z","timestamp":1788484721598,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272857"],"award-info":[{"award-number":["82272857"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802636"],"award-info":[{"award-number":["81802636"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>BRAF V600 mutation is the most common oncogenic alternation in melanoma and is visible in around 50% of cutaneous and 10%\u201315% of acral or mucosal subtypes. Currently, immunotherapy with anti\u2010PD\u20101 blockade and dual\u2010targeted therapy with Dabrafenib plus trametinib (D\u2009+\u2009T) target therapy have been approved as adjuvant therapies for Stage III melanoma with BRAF V600 mutation. According to their phase III clinical trials, 3\u2010year recurrence\u2010free survival (RFS) is around 60% for both types of treatment. However, early disease control was slightly more effective with targeted therapy than immunotherapy. With different drug approval deadlines in China, anti\u2010PD1 monotherapy, D\u2009+\u2009T combination, and Vemurafenib (V) monotherapy have all been used in real clinical practice as adjuvant settings for stage III BRAF\u2010mut melanoma in recent years. We conducted this retrospective study to evaluate the efficacy of different treatments in the Chinese melanoma population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients who underwent radical surgery and were diagnosed as Stage III melanoma harboring BRAF V600 mutation by pathological report were retrospectively identified at Fudan University Shanghai Cancer Center from January 2017 to December 2021. Patients with mucosal melanoma, or with follow\u2010up of &lt;6\u2009months, or receiving other adjuvant treatment were excluded. Pearson's chi\u2010squared test or Fisher's exact test was performed for univariable analysis of the different adjuvant groups. Log\u2010rank analysis was used to identify prognostic factors for relapse\u2010free survival (RFS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ninety\u2010three patients with resected stage III melanoma with BRAF V600E mutation were identified in our study, including 25 patients receiving adjuvant anti\u2010PD\u20101 immunotherapy (PD\u20101), 25 receiving adjuvant D\u2009+\u2009T, 23 receiving V, and 20 patients with observation\u2010only (OBS). There were no statistical differences between treatment groups in baseline characteristics including age, gender, subtypes, primary thickness, ulceration, and nodal involvement. Median relapse\u2010free survival (RFS) time was not reached in the D\u2009+\u2009T group, 15\u2009months in the V group, 15\u2009months in the PD\u20101 group, and 10\u2009months in the OBS group, respectively. Compared to OBS, all three other groups showed a tendency to benefit from RFS, while only D\u2009+\u2009T achieved a statistical difference (<jats:italic>p<\/jats:italic>\u2009=\u20090.002). However, compared to D\u2009+\u2009T, anti\u2010PD\u20101 monotherapy also showed significantly worse relapse control (<jats:italic>p<\/jats:italic>\u2009=\u20090.032).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>For Chinese stage III melanoma with BRAF mutation, both novel targeted therapy and immunotherapy showed potential benefits in relapse\u2010free survival compared to observation only. Dual\u2010targeted D\u2009+\u2009T therapy may still be the best choice for adjuvant therapy because anti\u2010PD\u20101 monotherapy has failed to report equivalent efficacy in real\u2010world practice.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.5866","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T03:08:31Z","timestamp":1680664111000},"page":"11475-11482","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative analysis of adjuvant therapy for stage <scp>III BRAF<\/scp>\u2010mut melanoma: A real\u2010world retrospective study from single center in China"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0332-8688","authenticated-orcid":false,"given":"Jingqin","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Musculoskeletal Surgery Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2151-6420","authenticated-orcid":false,"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjun","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-4566","authenticated-orcid":false,"given":"Yong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"issue":"21","key":"e_1_2_10_2_1","article-title":"Chinese guidelines on the diagnosis and treatment of melanoma (2015 edition)","volume":"3","author":"Guo J","year":"2015","journal-title":"Ann Transl Med"},{"issue":"4","key":"e_1_2_10_3_1","first-page":"63","article-title":"Epidemiology of melanoma","volume":"9","author":"Saginala K","year":"2021","journal-title":"Med Sci"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.V41N1p17"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0980"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904059"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30494-0"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02110"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30106-2"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005493"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6513-7"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00065-6"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.471"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01121-y"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9570"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-017-1685-3"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0143"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.02.007"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3922"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21241"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03532-2"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22071"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz005"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15103"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30417-7"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00533"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720044"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T12:48:04Z","timestamp":1695905284000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/cam4.5866"],"URL":"https:\/\/doi.org\/10.1002\/cam4.5866","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"assertion":[{"value":"2022-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}